Maf1, a novel negative transcriptional regulator of the TATA binding protein

Maf1,TATA 结合蛋白的新型负转录调节因子

基本信息

  • 批准号:
    8907912
  • 负责人:
  • 金额:
    $ 25.23万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2017-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): In the previous grant period, we made the unexpected discovery that members of the epidermal growth factor receptor family differentially regulate expression of the central transcription initiation factor, TBP, and defined new signaling pathways and transcription factors that regulate TBP expression. In addition to identifying positive regulators of TBP, we discovered a novel human protein, Maf1, which represses TBP transcription. Maf1 is an important transcriptional repressor that uniquely targets both RNA pol II- and pol III-transcribed genes that promote oncogenic transformation. Our new results support the idea that Maf1 is a key target of PTEN that is critical for its tumor suppressor function. Loss of PTEN results in a marked decrease in Maf1 expression; increased Maf1 expression suppresses cellular transformation in PTEN- deficient cells; and nuclear Maf1 expression is diminished in both mouse and human prostate cancers that are PTEN-deficient. Our overall goal is to understand the molecular and biological function of Maf1, and to use mouse models to determine whether the resultant decrease in Maf1 expression, by loss of PTEN, contributes to the development of prostate cancer. Aim 1 will identify Maf1 occupied regions genome- wide in primary human prostate epithelial cells. Given our newly identified interaction between Maf1 and the transcription factor Mediator CDK8 subcomplex, we will further test the novel hypothesis that Maf1 blocks the ability of this subcomplex to induce both RNA pol II- and III-dependent gene expression. These studies will define new paradigms by which transcription from different RNA polymerases are co-repressed, thus elucidating important gene repression pathways. Given that CDK8 is a potent oncoprotein, Aim 2 will further assess whether Maf1 abrogates CDK8-mediated oncogenic transformation. A transgenic mouse model will be established to test the idea that restoring Maf1 expression in PTEN-deficient mouse prostate will block or delay prostate intraepithelial neoplasia and tumorigenesis. Characterization of Maf1 will provide a new paradigm for how cells suppress a transformed phenotype and define a novel PTEN target whose loss is critical to the development of prostate cancer.
描述(由申请人提供):在先前的授权期间,我们意外地发现表皮生长因子受体家族的成员差异调节中心转录起始因子TBP的表达,并定义了调节TBP表达的新的信号通路和转录因子。除了鉴定TBP的正调控因子外,我们还发现了一种新的抑制TBP转录的人类蛋白Maf 1。Maf 1是一种重要的转录抑制因子,其独特地靶向促进致癌转化的RNA pol II和pol III转录基因。我们的新结果支持Maf 1是PTEN的关键靶点的观点,这对其肿瘤抑制功能至关重要。PTEN的缺失导致Maf 1表达的显著降低; Maf 1表达的增加抑制了PTEN缺陷型细胞中的细胞转化;并且在PTEN缺陷型的小鼠和人前列腺癌中,核Maf 1表达都减少。我们的总体目标是了解Maf 1的分子和生物学功能,并使用小鼠模型来确定由于PTEN的缺失而导致的Maf 1表达的降低是否有助于前列腺癌的发展。目的1将在原代人前列腺上皮细胞中鉴定Maf 1占据的全基因组区域。考虑到我们新发现的Maf 1和转录因子介体CDK 8亚复合物之间的相互作用,我们将进一步测试Maf 1阻断该亚复合物诱导RNA pol II和III依赖性基因表达的能力的新假设。这些研究将定义新的范例,通过这些范例,来自不同RNA聚合酶的转录被共阻遏,从而阐明重要的基因阻遏途径。鉴于CDK 8是一种有效的癌蛋白,Aim 2将进一步评估Maf 1是否消除CDK 8介导的致癌转化。将建立转基因小鼠模型来测试在PTEN缺陷小鼠前列腺中恢复Maf 1表达将阻断或延迟前列腺上皮内瘤形成和肿瘤发生的想法。Maf 1的表征将为细胞如何抑制转化的表型提供新的范例,并定义一种新的PTEN靶点,其丢失对前列腺癌的发展至关重要。

项目成果

期刊论文数量(23)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
MAF1, a repressor of RNA polymerase III-dependent transcription, regulates bone mass.
  • DOI:
    10.7554/elife.74740
  • 发表时间:
    2022-05-25
  • 期刊:
  • 影响因子:
    7.7
  • 作者:
    Phillips, Ellen;Ahmad, Naseer;Sun, Li;Iben, James;Walkey, Christopher J.;Rusin, Aleksandra;Yuen, Tony;Rosen, Clifford J.;Willis, Ian M.;Zaidi, Mone;Johnson, Deborah L.
  • 通讯作者:
    Johnson, Deborah L.
The TATA-Binding Protein as a Regulator of Cellular Transformation
  • DOI:
    10.4161/cc.2.5.493
  • 发表时间:
    2003-01-01
  • 期刊:
  • 影响因子:
    4.3
  • 作者:
    Johnson, Sandra A. S.;Dubeau, Louis;Johnson, Deborah L.
  • 通讯作者:
    Johnson, Deborah L.
PNRC is a unique nuclear receptor coactivator that stimulates RNA polymerase III-dependent transcription.
PNRC是一种独特的核受体共激活因子,可刺激RNA聚合酶III依赖性转录。
  • DOI:
    10.1186/1750-2187-2-5
  • 发表时间:
    2007-07-05
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Zhou, Dujin;Zhong, Shuping;Ye, Jing-Jing;Quach, Keith M;Johnson, Deborah L;Chen, Shiuan
  • 通讯作者:
    Chen, Shiuan
Maf1 and Repression of RNA Polymerase III-Mediated Transcription Drive Adipocyte Differentiation.
  • DOI:
    10.1016/j.celrep.2018.07.046
  • 发表时间:
    2018-08-14
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Chen CY;Lanz RB;Walkey CJ;Chang WH;Lu W;Johnson DL
  • 通讯作者:
    Johnson DL
A TATA element is required for tRNA promoter activity and confers TATA-binding protein responsiveness in Drosophila Schneider-2 cells.
TATA 元件是 tRNA 启动子活性所必需的,并在果蝇 Schneider-2 细胞中赋予 TATA 结合蛋白响应性。
  • DOI:
    10.1074/jbc.274.16.11369
  • 发表时间:
    1999
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Trivedi,A;Young,LS;Ouyang,C;Johnson,DL;Sprague,KU
  • 通讯作者:
    Sprague,KU
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DEBORAH L. JOHNSON其他文献

DEBORAH L. JOHNSON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DEBORAH L. JOHNSON', 18)}}的其他基金

Maf1, a novel negative transcriptional regulator of the TATA binding protein
Maf1,TATA 结合蛋白的新型负转录调节因子
  • 批准号:
    8868360
  • 财政年份:
    2014
  • 资助金额:
    $ 25.23万
  • 项目类别:
Novel targets that are deregulated by loss of PTEN
由于 PTEN 缺失而解除管制的新靶标
  • 批准号:
    8248605
  • 财政年份:
    2006
  • 资助金额:
    $ 25.23万
  • 项目类别:
Novel targets that are deregulated by loss of PTEN
由于 PTEN 缺失而解除管制的新靶点
  • 批准号:
    7544507
  • 财政年份:
    2006
  • 资助金额:
    $ 25.23万
  • 项目类别:
Novel targets that are deregulated by loss of PTEN
由于 PTEN 缺失而解除管制的新靶标
  • 批准号:
    7749054
  • 财政年份:
    2006
  • 资助金额:
    $ 25.23万
  • 项目类别:
Novel targets that are deregulated by loss of PTEN
由于 PTEN 缺失而解除管制的新靶点
  • 批准号:
    7343163
  • 财政年份:
    2006
  • 资助金额:
    $ 25.23万
  • 项目类别:
Novel targets that are deregulated by loss of PTEN
由于 PTEN 缺失而解除管制的新靶标
  • 批准号:
    8456058
  • 财政年份:
    2006
  • 资助金额:
    $ 25.23万
  • 项目类别:
Novel targets that are deregulated by loss of PTEN
由于 PTEN 缺失而解除管制的新靶标
  • 批准号:
    7176233
  • 财政年份:
    2006
  • 资助金额:
    $ 25.23万
  • 项目类别:
Novel targets that are deregulated by loss of PTEN
由于 PTEN 缺失而解除管制的新靶标
  • 批准号:
    7908332
  • 财政年份:
    2006
  • 资助金额:
    $ 25.23万
  • 项目类别:
Novel targets that are deregulated by loss of PTEN
由于 PTEN 缺失而解除管制的新靶标
  • 批准号:
    7045838
  • 财政年份:
    2006
  • 资助金额:
    $ 25.23万
  • 项目类别:
Novel targets that are deregulated by loss of PTEN
由于 PTEN 缺失而解除管制的新靶标
  • 批准号:
    8919255
  • 财政年份:
    2006
  • 资助金额:
    $ 25.23万
  • 项目类别:

相似海外基金

Role of anchorage-independent growth regulation in tumor progression
不依赖锚定的生长调节在肿瘤进展中的作用
  • 批准号:
    15K06829
  • 财政年份:
    2015
  • 资助金额:
    $ 25.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding the molecular mechanism required for an anchorage-independent growth of CD133-positive ovarian cancer cells
了解 CD133 阳性卵巢癌细胞非贴壁依赖性生长所需的分子机制
  • 批准号:
    23800055
  • 财政年份:
    2011
  • 资助金额:
    $ 25.23万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Anchorage-independent growth and EMT relationship in esophageal cancer.
食管癌的锚定非依赖性生长和 EMT 关系。
  • 批准号:
    23659637
  • 财政年份:
    2011
  • 资助金额:
    $ 25.23万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Functional analysis of a novel signal molecule CDCP1 which regulates anchorage-independent growth in cancer cells
调节癌细胞贴壁依赖性生长的新型信号分子CDCP1的功能分析
  • 批准号:
    21590350
  • 财政年份:
    2009
  • 资助金额:
    $ 25.23万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Pathophysiology of lymphatic stomata in the pathogenesis of cancerous pleural effusion and mechanisms of anchorage-independent growth of cancer
癌性胸腔积液发病机制中淋巴气孔的病理生理学和癌症非锚定依赖性生长机制
  • 批准号:
    20790993
  • 财政年份:
    2008
  • 资助金额:
    $ 25.23万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
  • 批准号:
    6513557
  • 财政年份:
    2000
  • 资助金额:
    $ 25.23万
  • 项目类别:
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
  • 批准号:
    6633392
  • 财政年份:
    2000
  • 资助金额:
    $ 25.23万
  • 项目类别:
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
  • 批准号:
    6042591
  • 财政年份:
    2000
  • 资助金额:
    $ 25.23万
  • 项目类别:
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
  • 批准号:
    6377153
  • 财政年份:
    2000
  • 资助金额:
    $ 25.23万
  • 项目类别:
ANCHORAGE INDEPENDENT GROWTH INDUCED BY CDC42
CDC42 带来的安克雷奇独立增长
  • 批准号:
    6771684
  • 财政年份:
    2000
  • 资助金额:
    $ 25.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了